Last post Fri, Apr 18 2008 9:15 AM by squiffy2. 0 replies.
Idera Pharmaceuticals, Inc, today presented data from studies evaluating a Toll-Like Receptor (TLR) antagonist in a preclinical model of multiple sclerosis (MS).The presentation entitled "Studies of Oligonucleotide-Based Antagonists of TLR9 in a Mouse Model of Experimental Autoimmune Encephalomyelitis" (Abstract #2049) was made during the 60th Annual Meeting of the American Academy of Neurology.In the study, one of the Company's proprietary TLR antagonist candidates was evaluated in a mouse model of experimental encephalomyelitis, a preclinical model of MS. Treatment with this antagonist candidate resulted in reductions of disease symptoms, including leg weakness and inflammatory cell infiltration in and demyelination of the spinal cord......... For the full report please go to MSRC: MS Research News : New Discoveries : Antibodies, B Cells,T-Cell Activation and Immune Response
